Nomura Asset Management Co. Ltd. Has $11.63 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Nomura Asset Management Co. Ltd. lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 97.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,476 shares of the medical device company’s stock after selling 6,004,705 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in DexCom were worth $11,625,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. New Age Alpha Advisors LLC bought a new stake in DexCom in the fourth quarter valued at about $14,702,000. Norges Bank acquired a new stake in DexCom during the fourth quarter valued at approximately $385,367,000. NEOS Investment Management LLC grew its stake in shares of DexCom by 15.3% in the 4th quarter. NEOS Investment Management LLC now owns 76,172 shares of the medical device company’s stock valued at $5,924,000 after purchasing an additional 10,113 shares during the period. Sava Infond d.o.o. bought a new position in shares of DexCom during the 4th quarter worth approximately $474,000. Finally, Elo Mutual Pension Insurance Co lifted its position in shares of DexCom by 14.1% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 40,159 shares of the medical device company’s stock worth $3,123,000 after buying an additional 4,968 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last quarter. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $67.74 on Monday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $26.47 billion, a P/E ratio of 47.37, a PEG ratio of 2.30 and a beta of 1.28. The business has a 50-day moving average of $82.32 and a 200-day moving average of $77.13. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $141.99.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of several recent analyst reports. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.